VPC
PYXS icon

Vestal Point Capital’s Pyxis Oncology PYXS Stock Holding History

Vestal Point Capital’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-440,000
Closed -$792K – 70
2023
Q4 		$792K Buy
+440,000
New +$754K 0.08% 40

Other funds holding PYXS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vestal Point Capital's PYXS Position: Q1 2024 in Review

Vestal Point Capital sold out of Pyxis Oncology (PYXS) in Q1 2024, closing a stake of 440,000 shares — an estimated $792K sold.

Vestal Point Capital first reported a position in PYXS in Q4 2023 and held it in 1 quarter. The position peaked at $792K in Q4 2023. 72 funds tracked by Wall St. Rank hold PYXS as of Q1 2024.

  • Vestal Point Capital reported no remaining Pyxis Oncology position as of Q1 2024 after selling out during the quarter.
  • Vestal Point Capital sold 440,000 Pyxis Oncology shares in Q1 2024, an estimated $792K.
  • Vestal Point Capital first reported a position in Pyxis Oncology in Q4 2023 and held it in 1 quarter.
  • Vestal Point Capital's Pyxis Oncology position peaked at $792K in Q4 2023.
  • 72 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.